Expert Review of Vaccines最新文献_第2页

Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary. 在儿童、青少年和成人中使用研究性莱姆病疫苗加强接种：简单的语言总结。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-27 DOI: 10.1080/14760584.2026.2722004

Laura Wagner, Marc Messier, James H Stark, Erik Lamberth

引用次数: 0

COVID-19 in pediatrics in Latin America: six years later. 6年后，儿科的新冠肺炎

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-04 DOI: 10.1080/14760584.2026.2667741

María L Ávila-Aguero, Helena Brenes-Chacon, Luiza Helena Falleiros-Arlant, José Brea-Del Castillo, Alejandra Soriano-Fallas, Gabriela Naranjo-Zúñiga, Xavier Sáez-Llorens, Angela Gentile, Eduardo Lopez-Medina, Flor M Muñoz

{"title":"COVID-19 in pediatrics in Latin America: six years later.","authors":"María L Ávila-Aguero, Helena Brenes-Chacon, Luiza Helena Falleiros-Arlant, José Brea-Del Castillo, Alejandra Soriano-Fallas, Gabriela Naranjo-Zúñiga, Xavier Sáez-Llorens, Angela Gentile, Eduardo Lopez-Medina, Flor M Muñoz","doi":"10.1080/14760584.2026.2667741","DOIUrl":"10.1080/14760584.2026.2667741","url":null,"abstract":"Introduction: Six years later, the impact of the COVID-19 pandemic on children in Latin America remains profound. Even though they were considered less susceptible to the disease, infants have emerged as one of the most affected populations, with the pandemic exposing deep inequities and magnifying vulnerabilities. This paper is presented as a perspective from SLIPE on COVID-19, providing expert insight into the current epidemiological situation in the region.Areas covered: This review analyzes the effects of the COVID-19 pandemic on children's health and wellbeing, education, and immunization efforts. Vaccination coverage against COVID-19 in children is suboptimal, particularly among those with high-risk underlying conditions, and the disruption of routine immunization programs has led to outbreaks of vaccine preventable diseases in the region.Expert opinion: Addressing these challenges requires strengthening both COVID-19 vaccination strategies for high-risk pediatric populations and routine childhood immunization programs, along with effective communication to combat misinformation, prioritization of educational recovery, social protection, and resilient health systems. Recovery must focus on closing inequity gaps and placing children at the center of public policy to safeguard their future.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2667741"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physician recommendation and vaccine hesitancy as key drivers of pneumococcal vaccination among older adults in China: a cross-sectional study using policy-stratified structural equation modeling. 医生推荐和疫苗犹豫是中国老年人肺炎球菌疫苗接种的关键驱动因素：一项使用政策分层结构方程模型的横断面研究

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-04-26 DOI: 10.1080/14760584.2026.2645379

Yuxing Wang, Shuai Yuan, Yuanruo Xie, Jianing Dai, Ling Zhu, Gang Liu, Zhujiazi Zhang, Lili You

{"title":"Physician recommendation and vaccine hesitancy as key drivers of pneumococcal vaccination among older adults in China: a cross-sectional study using policy-stratified structural equation modeling.","authors":"Yuxing Wang, Shuai Yuan, Yuanruo Xie, Jianing Dai, Ling Zhu, Gang Liu, Zhujiazi Zhang, Lili You","doi":"10.1080/14760584.2026.2645379","DOIUrl":"10.1080/14760584.2026.2645379","url":null,"abstract":"Background: Pneumococcal disease causes severe illness in older adults. This study examined the impacts of physician recommendation, vaccine hesitancy, and regional policy differences on pneumococcal vaccination uptake in China.Research design and methods: A cross-sectional study was conducted among 13,363 adults aged ≥ 60 years in six Chinese cities using structural equation modeling, stratified by free and self-financed vaccination areas.Results: Mean age was 69.53 years, 54.74% female, with 22.79% vaccination rate. Vaccine hesitancy had a significant negative direct effect on vaccination uptake (β = -0.387, p < 0.001), while physician recommendation exerted the largest total positive effect (β = 0.349). In self-financed policy area, vaccine hesitancy was the strongest negative predictor (β = -0.529, p < 0.001), and diverse information sources mitigated hesitancy but showed a slight negative direct effect on uptake (β = -0.059).In the free-vaccine policy area, physician recommendation had a more pronounced direct effect (β = 0.305, p < 0.001), and better perceived health status was associated with suppressed uptake (β = -0.093).Conclusions: Vaccine attitudes often reflect generalized psychological constructs. Strategies must be tailored to policy contexts: enhancing information quality in self-financed areas and addressing complacency in free-vaccine settings. Multidimensional interventions should expand healthcare worker roles and optimize organizational logistics. Key limitations include the cross-sectional design and reliance on self-reported data.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2645379"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-11 DOI: 10.1080/14760584.2026.2629653

引用次数: 0

Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges. 在高危人群中预防COVID-19：开发下一代mRNA-1283 COVID-19疫苗以应对当前挑战

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-03 DOI: 10.1080/14760584.2026.2632657

Joseph B Domachowske, Gregory D Zimet, William Hanage, Ekkehard Beck, Preeti Sule, Rahnuma Wahid, Nevena Vicic

{"title":"Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges.","authors":"Joseph B Domachowske, Gregory D Zimet, William Hanage, Ekkehard Beck, Preeti Sule, Rahnuma Wahid, Nevena Vicic","doi":"10.1080/14760584.2026.2632657","DOIUrl":"10.1080/14760584.2026.2632657","url":null,"abstract":"Introduction: Next-generation COVID-19 vaccines hold promise to reduce severe outcomes in populations most at risk. While the original mRNA COVID-19 vaccine, mRNA-1273, targets the full-length SARS-CoV-2 spike protein, mRNA-1283 is a novel next-generation mRNA COVID-19 vaccine that specifically targets immunodominant domains within the spike protein.Areas covered: This review summarizes literature on the development of mRNA-1283, from its design and preclinical evaluation to phase 1-3 clinical trial findings, with a particular focus on immunogenicity and efficacy in at-risk populations, specifically older adults and adults with comorbidities. The potential public health impact of this next-generation vaccine is explored, along with ongoing challenges facing COVID-19 vaccination.Expert opinion: Phase 1-3 clinical trials demonstrated that mRNA-1283 was well-tolerated and no safety concerns were identified. Furthermore, mRNA-1283 demonstrated higher point estimates of immunogenicity and relative vaccine efficacy than mRNA-1273, including among older adults and individuals with underlying conditions who are most susceptible to severe COVID-19. Initial modeling studies indicate that mRNA-1283 could prevent more hospitalizations than current COVID-19 vaccines. Evidence to date suggests that the novel next-generation mRNA-1283 vaccine holds promise to advance progress in reducing the ongoing burden of COVID-19 across vulnerable populations.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2632657"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147304125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study. 佐剂rsvpref3疫苗在COPD患者中的吸收和有效性：一项丹麦全国队列研究

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-10 DOI: 10.1080/14760584.2026.2641671

Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland

{"title":"Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.","authors":"Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland","doi":"10.1080/14760584.2026.2641671","DOIUrl":"10.1080/14760584.2026.2641671","url":null,"abstract":"Background: Individuals with chronic obstructive pulmonary disease (COPD) face increased risk of severe respiratory syncytial virus (RSV)-related outcomes. We assessed the uptake of adjuvanted-RSVPreF3 and its effectiveness against RSV hospitalization in such individuals.Research design and methods: We assembled a Danish nationwide cohort of individuals aged ≥ 60 years with COPD during the 2024/25 RSV season. Vaccinated and unvaccinated individuals were matched using exact and propensity score matching resulting in balanced groups. Individuals were followed from 21 days post-vaccination until the earliest of event, end of data availability, migration, RSV vaccination, or death. Vaccine effectiveness was estimated as (1 - incidence rate ratio [IRR]) x 100, where IRRs were calculated using observed event counts and accumulated person-time. Confidence intervals (CIs) were based on Poisson distributions.Results: Among 126,249 eligible individuals, 7,448 (5.9%) received adjuvanted-RSVPreF3. RSV hospitalization rates per 100,000 person-years were 0.0 (95% CI: 0.0-58.0) for vaccinated individuals and 200.6 (165.6 - 240.8) for unvaccinated individuals, yielding an effectiveness of 100.0% (71.1-100.0). Incidences of other RSV-related outcomes were lower among vaccinated individuals.Conclusions: Adjuvanted-RSVPreF3 is highly effective in preventing RSV hospitalization in individuals aged ≥60 years with COPD. Disease outcomes could be improved by incorporating RSV vaccination into routine COPD management.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2641671"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE). 大流行后对侵袭性肺炎球菌疾病流行病学的影响：拉丁美洲儿科传染病学会（SLIPE）的共识声明。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-06-19 DOI: 10.1080/14760584.2026.2689604

Roberto Debbag, María L Avila-Agüero, Angela Gentile, Jaime Torres, Carlos Torres, Liliana Vazquez, Claudia Beltran, José Brea-Del Castillo, Ron Dagan

{"title":"Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).","authors":"Roberto Debbag, María L Avila-Agüero, Angela Gentile, Jaime Torres, Carlos Torres, Liliana Vazquez, Claudia Beltran, José Brea-Del Castillo, Ron Dagan","doi":"10.1080/14760584.2026.2689604","DOIUrl":"10.1080/14760584.2026.2689604","url":null,"abstract":"Introduction: The Latin American Society of Pediatric Infectious Diseases (SLIPE) convened a multidisciplinary expert panel to assess the post-pandemic epidemiology of invasive pneumococcal disease (IPD) in Latin America and the Caribbean. The COVID-19 pandemic initially reduced IPD incidence due to non-pharmaceutical interventions, but subsequent relaxation of restrictions, coupled with immunization gaps, led to a resurgence of pneumococcal infections. The consensus statement reviews literature and regional surveillance data to analyze how disrupted vaccination programs, socioeconomic inequities, and weakened healthcare systems amplified the regional vulnerability to vaccine-preventable diseases.Areas covered: This document addresses epidemiologic changes in IPD following the pandemic, the interplay between respiratory viral infections and pneumococcal disease, trends in pneumococcal conjugate vaccine (PCV) coverage and related barriers, and the emergence of non-vaccine serotypes causing IPD.Expert opinion: Sustaining herd protection in the region requires strengthening vaccination infrastructure, restoring confidence through effective communication, and ensuring the completion of booster doses in the second year of life. Despite limited serotype data, countries should prioritize the timely adoption of higher-valency PCVs in feasible schedules to mitigate the growing burden of pneumococcal disease and prevent further setbacks in child health.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2689604"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis. 评估瑞典成人呼吸道疫苗接种的社会价值：效益-成本分析。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-07-02 DOI: 10.1080/14760584.2026.2689614

Ellie Tunnicliffe, Matthew Napier, Claud Theakston, Soo Chin Yen, Sukanya Subramaniyan, Simon Brassel, Fredrik Nilsson, Katherina Zakikhany-Gilg, Andreas Palmborg, Mate Szilcz, Samira Toghanian, Pontus Hedberg, Mikael Svensson, Tianyan Hu, Jingyan Yang, Lotte Steuten

{"title":"Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.","authors":"Ellie Tunnicliffe, Matthew Napier, Claud Theakston, Soo Chin Yen, Sukanya Subramaniyan, Simon Brassel, Fredrik Nilsson, Katherina Zakikhany-Gilg, Andreas Palmborg, Mate Szilcz, Samira Toghanian, Pontus Hedberg, Mikael Svensson, Tianyan Hu, Jingyan Yang, Lotte Steuten","doi":"10.1080/14760584.2026.2689614","DOIUrl":"10.1080/14760584.2026.2689614","url":null,"abstract":"Background: In Sweden, older adults and adults in clinical risk groups are recommended vaccination against pneumococcal disease, respiratory syncytial virus, influenza, and COVID-19. However, vaccine uptake remains inadequate. This study estimates the socioeconomic benefits of these immunization programs under current coverage compared to aspirational scenarios, assessing the value foregone due to suboptimal uptake.Methods: We conducted a benefit-cost analysis from a societal perspective applying life table-based disease models to estimate benefit-cost ratios (BCRs) and net benefits (NBs). Health impacts were monetized through the value-of-a-statistical-life and cost-of-illness approaches. Costs comprised vaccination program expenses. Scenario and sensitivity analyses explore coverage and program eligibility.Results: Vaccination programs in older adults generated BCRs of 3:1 and NBs of SEK 54.4 billion over a lifetime (VSLY). When risk groups were included to model current strategies in Sweden, NBs increased to SEK 59.7 billion. Reaching aspirational coverage targets increased NBs by 18%, meanwhile restricting eligibility reduced NBs by 64%.Conclusion: Adult respiratory vaccinations in Sweden provide substantial value for the healthcare system, economy and society, with estimated benefits exceeding costs under modeled assumptions. These findings may inform policy discussions on strategies to sustain or expand vaccination budgets, improve access and increase uptake, particularly among at-risk populations.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2689614"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

United States healthcare providers' views on pediatric meningococcal disease and vaccination. 美国医疗保健提供者对儿童脑膜炎球菌病和疫苗接种的看法。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-01 DOI: 10.1080/14760584.2026.2721744

Oscar Herrera-Restrepo, Vasudha Gupta, Sophie Jacobovitz, Tosin Olaiya, Elise Kuylen, Karam Dahyaleh, Kristin K Johnson, Thatiana Pinto, Sofia B Pinto, Jana Shaw

{"title":"United States healthcare providers' views on pediatric meningococcal disease and vaccination.","authors":"Oscar Herrera-Restrepo, Vasudha Gupta, Sophie Jacobovitz, Tosin Olaiya, Elise Kuylen, Karam Dahyaleh, Kristin K Johnson, Thatiana Pinto, Sofia B Pinto, Jana Shaw","doi":"10.1080/14760584.2026.2721744","DOIUrl":"10.1080/14760584.2026.2721744","url":null,"abstract":"Background: Although meningococcal serogroup B (MenB) causes most invasive meningococcal disease (IMD) cases in United States (US) infants, MenB vaccination is not currently approved for this age group. This study sought to better understand US healthcare providers' (HCPs') views regarding IMD and a potential MenB vaccine for children ≤18 months old.Research design and methods: An online survey was conducted in November 2024 among US board-certified HCPs who provided care to children ≤18 months old. Responses were analyzed descriptively.Results: Among N = 506 HCPs, 97.8% responded that, if the Advisory Committee on Immunization Practices (ACIP) were to recommend MenB vaccination for children ≤18 months old, it should be recommended for all children in this age group (52.6%) or those at increased risk for IMD (45.3%). Less than one-fifth (17.6%) of HCPs correctly identified the ACIP MenB vaccination recommendation for children ≤18 months old; 84.4% indicated interest in learning more about a potential MenB vaccine if ACIP-recommended for this population. When considering recommending potential MenB vaccination, 68.6% of HCPs anticipated encountering vaccine hesitancy among parents/caregivers.Conclusions: Most HCPs viewed infant MenB vaccination favorably but demonstrated knowledge gaps regarding IMD epidemiology and vaccine recommendations, underscoring the need for targeted education to optimize future IMD prevention.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2721744"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence and efficacy of the 0 - 7 - 21-day versus the 0 - 1 - 6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial. 在使用药物的人群中，0 - 7 - 21天与0 - 1- 6个月乙肝疫苗接种计划的依从性和有效性：一项为期两年的随机对照试验

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-08 DOI: 10.1080/14760584.2026.2626920

Xianbin Hou, Ning Li, Hailan Zhang, Wenjun Liu, Haichao Zheng, Tianyi Zhuang, Zhuoru Zou, Ruyi Xia, Ying Liu, Hongyan Zhang, Tiejun Hou, Zhijun Chen, Baozhong Chen, Fuzhen Wang, Lirong Wang, Xiaoli Wei, Guihua Zhuang

{"title":"Adherence and efficacy of the 0 - 7 - 21-day versus the 0 - 1 - 6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial.","authors":"Xianbin Hou, Ning Li, Hailan Zhang, Wenjun Liu, Haichao Zheng, Tianyi Zhuang, Zhuoru Zou, Ruyi Xia, Ying Liu, Hongyan Zhang, Tiejun Hou, Zhijun Chen, Baozhong Chen, Fuzhen Wang, Lirong Wang, Xiaoli Wei, Guihua Zhuang","doi":"10.1080/14760584.2026.2626920","DOIUrl":"10.1080/14760584.2026.2626920","url":null,"abstract":"Background: To compare the adherence and efficacy between the 0 - 7 - 21-day and the 0 - 1 - 6-month hepatitis B virus (HBV) vaccination schedules among people who use drugs (PWUD) in China.Research design and methods: A randomized controlled trial was conducted in 1261 HBV-susceptible PWUD from compulsory isolated detoxification centers (CIDCs) and methadone maintenance treatment (MMT) clinics in Xi'an. A 20 µg per-dose vaccine was used. HBV surface antibody (anti-HBs), surface antigen, and core antibody were tested at months 7, 15, and 22 after the first dose.Results: Third-dose coverage was significantly higher in the 0 - 7 - 21-day group (74.40%) than in the 0 - 1 - 6-month group (51.58%, p < 0.001), mainly driven by participants from CIDCs (77.75% vs. 45.69%). Anti-HBs positive rates at months 7, 15, and 22 among participants who completed all three doses were significantly higher for the 0 - 1 - 6-month schedule (90.71%, 76.82%, and 67.35%) than for the 0 - 7 - 21-day schedule (74.23%, 49.40%, and 40.95%; all p < 0.001). HBV infection incidence was similar between schedules, but significantly different between vaccinees and non-vaccinees (p = 0.018).Conclusions: The 0 - 7 - 21-day schedule substantially enhances three-dose completion in PWUD, but induces a notably weaker anti-HBs response and persistence. Schedules should be selected based on the management models for PWUD and their individual characteristics.Clinical trial registration: Chinese Clinical Trial Registry (ChiCTR1900022403).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626920"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0